IMR Press / CEOG / Volume 36 / Issue 4 / pii/1630635893835-318724737

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Tartrate-resistant acid phosphatase (TRAP) as a serum marker for bone resorption in breast cancer patients with bone metastases
Show Less
1 Department of Gynaecology and Obstetrics, Caritas Hospital St Theresia, Saarbrücken
2 Department of Gynaecology and Obstetrics, University Schleswig-Holstein, Campus Luebeck, Luebeck
3 Department of Gynaecology and Obstetrics, Leverkusen
4 Department of Gynaecology and Obstetrics, HELIOS-Klinikum Krefeld, Krefeld (Germany)
Clin. Exp. Obstet. Gynecol. 2009, 36(4), 219–225;
Published: 10 December 2009

Background: A novel immunoassay specific for the osteoclast-produced tartrate-resistant acid phosphatase TRAP isoform 5b was developed some years ago. By means of this assay, the usefulness of serum TRAP in monitoring the response to palliative treatment with clodronate in breast cancer patients with bone metastases was studied. Serum TRAP was examined for correlation with the activity of bone osteoclasts in these patients. Materials and Methods: Seventeen patients took part in this study taking 1600 mg clodronate daily as a tablet for five months. Eleven of these patients were evaluated. Results: TRAP activity correlated well with the grade of bone metastases and with the number of locations in the body. During the therapy with clodronate, TRAP activity in serum decreased. Conclusions: We conclude that the measurement of TRAP is useful in monitoring treatment with bisphosphonate clodronate in patients with bone metastatic breast cancer.
Tartrate-resistant acid phosphatase (TRAP)
Bone metastases
Back to top